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Here,  we  used  MCF7  cells  as  a  model  system  to  interrogate  how  MYC/RAS  co‐operativity  contributes  to
metabolic  flux  and  stemness  in  breast  cancer  cells. We  compared  the  behavior  of  isogenic MCF7  cell  lines
transduced with c‐Myc or H‐Ras  (G12V), either  individually or  in combination. Cancer stem cell  (CSC) activity
was  measured  using  the  mammosphere  assay.  c‐Myc  augmented  both  mammosphere  formation  and
mitochondrial  respiration,  without  any  effects  on  glycolytic  flux.  In  contrast,  H‐Ras  (G12V)  synergistically
augmented  both  mammosphere  formation  and  glycolysis,  but  only  in  combination  with  c‐Myc,  directly
demonstrating  MYC/RAS  co‐operativity.  As  c‐Myc  is  known  to  exert  its  effects,  in  part,  by  stimulating
mitochondrial biogenesis, we next  examined  the  effects of  another  stimulus  known  to  affect mitochondrial
biogenesis,  i.e.  ROS  production.  To  pharmacologically  induce  oxidative  stress,  we  used  Rotenone  (a
mitochondrial inhibitor) to target mitochondrial complex I. Treatment with Rotenone showed bi‐phasic effects;
low‐dose Rotenone (1 to 2.5 nM) elevated mammosphere formation, while higher doses (10 to 100 nM) were
inhibitory.  Importantly,  the  stimulatory  effects  of  Rotenone  on  CSC  propagation  were  blocked  using  a
mitochondrial‐specific  anti‐oxidant,  namely  Mito‐tempo.  Thus,  “mild”  mitochondrial  oxidative  stress,
originating  at  Complex  I,  was  sufficient  to  pheno‐copy  the  effects  of  c‐Myc,  effectively  promoting  CSC
propagation. To validate the  idea that mitochondrial biogenesis  is required to stimulate CSC propagation, we
employed  Doxycycline,  a  well‐established  inhibitor  of  mitochondrial  protein  translation.  Treatment  with
Doxycycline was indeed sufficient to block the stimulatory effects of H‐Ras (G12V), c‐Myc, and Rotenone on CSC
propagation.  As  such,  Doxycycline  provides  a  strong  rationale  for  designing  new  therapeutics  to  target
mitochondrial biogenesis, suggesting a new “mutation‐independent” approach to cancer therapy. In support of
this  notion,  most  currently  successful  anti‐cancer  agents  therapeutically  target  “cell  phenotypes”,  such  as
increased  cell  proliferation,  rather  than  specific  genetic  mutations.  Remarkably,  we  demonstrated  that
Doxycycline inhibits the effects of diverse oncogenic stimuli, of both i) genetic (MYC/RAS) and ii) environmental
(Rotenone) origins. Finally, we discuss the advantages of our “Proteomics‐to‐Genomics (PTG)” approach for in
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INTRODUCTION 
 
Historically, the c-Myc and H-Ras genes have played a 
major role in our understanding of how genetics 
contributes to the pathogenesis of human cancers [1]. 
Originally, both H-Ras and c-Myc were identified as 
viral oncogenes that were “stolen” from the cellular 
genome; they were shown to confer the oncogenic 
potential of RNA tumor viruses [2]. Later, it was 
directly confirmed that they are indeed derived from 
normal cellular proto-oncogenes that can be dys-
regulated by genetic amplification and/or by specific 
activating mutations [3]. 
 
The concept that multiple genetic changes or “hits” are 
additive, resulting in a step-wise progression towards 
cellular transformation, also derives from studies using 
c-Myc and H-Ras. More specifically, these pioneering 
studies showed that c-Myc and mutant H-Ras co-
operate, in promoting cell transformation and tumori-
genesis [4, 5]. 
 
However, mechanistically it still remains largely 
unknown exactly how c-Myc and H-Ras co-operate to 
promote or facilitate the process of oncogenic trans-
formation. Here, we specifically examined their role in 
the promotion of stem-like characteristics and metabolic 
phenotypes in cancer cells. For this purpose, we created 
a panel of MCF7 breast cancer cell lines, transduced 
with the cDNA’s encoding c-Myc or H-Ras (G12V), 
either individually or in combination. This provides a 
new epithelial-based isogenic model to study the 
cellular mechanisms underpinning oncogene co-
operation.  
 
Our results indicate that c-Myc and H-Ras (G12V) act 
synergistically to increase the capacity of cancer cells to 
undergo anchorage-independent growth and to amplify 
their energetic activity, effectively increasing both i) 
mitochondrial respiration (c-Myc) and ii) the glycolytic 
pathway (H-Ras (G12V)). Importantly, treatment with 
Doxycycline (a well-established inhibitor of mito-
chondrial biogenesis) was sufficient to halt and/or 
prevent the increases in CSC propagation driven by c-
Myc and H-Ras (G12V). Thus, our results suggest that 
inhibition of mitochondrial biogenesis may be a new 





MYC-RAS co-operativity increases “stemness”, 
mitochondrial respiration and glycolytic activity 
 
In order to investigate the mechanism(s) underlying 
MYC-RAS co-operativity, we first created a panel of 
isogenic MCF7 cell lines using lentiviral vectors 
(Figure 1). Briefly, MCF7 cells were transduced with 
either c-Myc alone or H-Ras (G12V) alone, or 
sequentially transduced with both c-Myc and H-Ras 
(G12V), using two different selectable markers. A 
series of empty vector control cell lines were also 
produced in parallel, to normalize for possible effects 
due to the process of lentiviral transduction.  This 























Figure 2 shows that oncogenic H-Ras alone surprisingly 
had no effect on mammosphere formation. Mammo-
sphere formation is generally regarded as a measure of 
CSC activity and/or the ability of cells to undergo 
anchorage-independent growth. In contrast, c-Myc was 
sufficient to increase mammosphere formation by ~2.3-
fold.  In addition, co-expression of c-Myc and H-Ras 
(G12V) maximally elevated mammosphere formation 
by ~3.15-fold.  
 
To better understand how MYC-RAS co-operativity 
fuels CSC propagation, we next subjected the panel of 
MCF7 cells to metabolic phenotyping, using the 
Seahorse XFe96 metabolic flux analyzer. Figure 3 
illustrates that c-Myc increases mitochondrial 
respiration, either alone or in combination with H-Ras 
(G12V). Interestingly, H-Ras (G12V) specifically 
increased glycolysis, but only in the cells transduced 
with c-Myc (Figure 4).  
 
Proteomics analysis identifies c-Myc targets: 
treatment with Doxycycline 
 
Based on our initial findings, it appeared that c-Myc had 
the largest effects on both “stemness” and cellular 
Figure  1.  Experimental  strategy  for  understanding
MYC/RAS  co‐operativity  in  human  breast  CSCs.  More
specifically, we examined how MYC/RAS  co‐operation affects
cellular  metabolism  and  CSC  propagation,  allowing  for  the
identification of a common metabolic therapy.  
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metabolism, relative to H-Ras (G12V). Thus, we focused 






















































proteomics analysis on MCF7 cells harboring c-Myc 
























































Symbol  Gene Description        Fold-Upregulation
             
CHCHD2 Putative coiled-coil-helix-coiled-coil-helix domain-containing protein, mitochondrial   4.05  
PRDX3  Thioredoxin-dependent peroxide reductase, mitochondrial    3.96  
COX5A  Cytochrome c oxidase subunit 5A, mitochondrial      3.65  
IMMT  Mitochondrial inner membrane protein       3.54  
TRNT1   CCA tRNA nucleotidyltransferase 1, mitochondrial      3.22  
TIMM44 Mitochondrial import inner membrane translocase subunit TIM44    3.15  
C21orf33  ES1 protein homolog, mitochondrial (HES1)     3.00  
AKAP1  A kinase anchor protein 1, mitochondrial       2.72  
MDH2  Malate dehydrogenase, mitochondrial (EC 1.1.1.37)      2.69  
IDH3A   Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial    2.64  
TRAP1  Heat shock protein 75 kDa, mitochondrial      2.40  
FASN   Fatty acid synthase        2.16  
HADHB Trifunctional enzyme subunit beta, mitochondrial     2.13  
CLUH   Clustered mitochondria protein homolog/KIAA0664     2.12  
ATP5I   ATP synthase subunit e, mitochondrial      1.98  
ABAT  4-aminobutyrate aminotransferase, mitochondrial     1.97 
CLPX  ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial  1.94  
HSPD1  60 kDa heat shock protein, mitochondrial      1.89  
SLIRP  SRA stem-loop-interacting RNA-binding protein, mitochondrial    1.81  
TUFM  Elongation factor Tu, mitochondrial      1.75  
COX5B  Cytochrome c oxidase subunit 5B, mitochondrial     1.69  
PDHB  Pyruvate dehydrogenase E1 component subunit beta, mitochondrial   1.64  
UQCR11 Cytochrome b-c1 complex subunit       1.64  
SUCLG2 Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial   1.60  
NDUFS1  Mitochondrial NADH-ubiquinone oxidoreductase 75 kDa subunit   1.51  
TOMM7  Mitochondrial import receptor subunit TOM7 homolog     1.49  
Figure  2.  MYC‐RAS  co‐operativity  augments  mammosphere  formation. Note  that  stable  transduction  with  H‐Ras
(G12V)  alone  has  no  effect  on  mammosphere  formation.  In  contrast,  transduction  with  c‐Myc  increases  mammosphere
formation by ~2.3‐fold. Finally, co‐transduction with c‐Myc and H‐Ras (G12V) synergistically increases mammosphere formation
by ~3.15‐fold, as compared to vector alone controls. Therefore, MYC‐RAS co‐operativity augments “stemness” in cancer cells.  



















































Most notably, ~26 mitochondrial proteins were 
elevated in MCF7-c-Myc cells, relative to vector alone 
control MCF7 cells. Importantly, many of these 
proteins are associated with either i) OXPHOS 




















































ii) the TCA cycle (MDH2, IDH3A, PDHB, and 
SUCLG2), iii) mitochondrial biogenesis (IMMT, 
TIMM44, TRAP1, HSPD1, SLIRP, TUFM, and 
TOMM7), or iv) mitochondrial oxidative stress 
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Therefore, we conclude that it may be possible to use 
mitochondrial inhibitors to target c-Myc amplification 
in CSCs. To test this hypothesis more directly, we used 
a well-known FDA-approved antibiotic (Doxycycline) 
that inhibits mitochondrial biogenesis as an off-target 
effect. Doxycycline is relatively non-toxic and has an 
excellent safety profile and is well-tolerated by patients, 

















































As predicted, Figure 5 shows that MYC-RAS-induced 
mammosphere formation is sensitive to Doxycycline 
treatment. However, mammosphere formation in 
MCF7-H-Ras (G12V) cells is more resistant to 
Doxycycline, but this was easily overcome by using 
higher doses of Doxycycline. These findings provide 
further evidence that mitochondrial biogenesis is clearly 



















































www.aging‐us.com  2103  AGING 
Low-dose Rotenone augments mammosphere 
formation: Reversal with a mitochondrial anti-
oxidant (Mito-tempo) or Doxycycline 
 
Based on the proteomics analysis presented in Table 1, 
we observed that c-Myc induced the expression of a 
powerful mitochondrial anti-oxidant (PRDX3), as well 
as a key component of mitochondrial complex I 
(NDUFS1). Other components of complex III, IV and V 















































Importantly, PRDX3 is normally over-expressed in 
response to mitochondrial oxidative stress [6]. NDUFS1 
is the core subunit of complex I; this protein product 
harbors both the NADH dehydrogenase and 
oxidoreductase activities [7]. NDUFS1 is the largest 
component of complex I and contains the iron-sulfur 
binding site [7]. 
 
Similarly, CHCHD2 expression was also strongly 














































Table 2. Myc-targets transcriptionally up-regulated in human breast cancer in vivo (Cancer Epithelia vs. Tumor Stroma).  
Symbol  Gene Description         Fold-Upregulation  P-value 
 
CHCHD2 Putative coiled-coil-helix domain-containing protein, mitochondrial    5.79   1.85E-07 
COX5B   Cytochrome c oxidase subunit 5B, mitochondrial     5.03   2.86E-06  
PRDX3  Thioredoxin-dependent peroxide reductase, mitochondrial    4.99   3.30E-06  
IMMT  Mitochondrial inner membrane protein       4.71   8.89E-06 
PDHB  Pyruvate dehydrogenase E1 component subunit beta, mitochondrial   4.51   1.75E-05  
MDH2  Malate dehydrogenase, mitochondrial (EC 1.1.1.37)     4.18   5.32E-05 
COX5A   Cytochrome c oxidase subunit 5A, mitochondrial     3.62   3.22E-04  
C21orf33  ES1 protein homolog, mitochondrial (HES1)     3.60   3.49E-04  
UQCR11  Cytochrome b-c1 complex subunit (UQCR)      3.43   5.87E-04 
HSPD1  60 kDa heat shock protein, mitochondrial     3.42   5.93E-04  
TUFM  Elongation factor Tu, mitochondrial      3.38   6.74E-04 
AKAP1  A kinase anchor protein 1, mitochondrial      3.33   7.75E-04 
NDUFS1  Mitochondrial NADH-ubiquinone oxidoreductase 75 kDa subunit   3.20   1.15E-03  
HADHB  Trifunctional enzyme subunit beta, mitochondrial     3.06   1.73E-03  
SUCLG2  Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial   3.03   1.89E-03  
TOMM7   Mitochondrial import receptor subunit TOM7 homolog     3.03   1.85E-03  
ATP5I   ATP synthase subunit e, mitochondrial       3.01   1.97E-03 
IDH3A   Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial   2.16   1.78E-02  
CLPX  ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial  2.11   1.96E-02  




Figure  5.  MYC‐RAS‐induced  mammosphere  formation  remains  sensitive  to
Doxycycline treatment. Note that mammosphere formation  in MCF7‐H‐Ras (G12V) cells
is more resistant to Doxycycline, but this can be overcome by using slightly higher dosages.  
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suggested to function as a ROS scavenger, while at the 
same time optimizing OXPHOS and other anti-
apoptotic mitochondrial functions [8].  
 
Taken together, these findings are consistent with the 
idea that c-Myc induces “stemness” in part by driving 
and effectively managing the onset of mitochondrial 

















































To test this working hypothesis, we next used a 
pharmacological approach, to chemically stimulate 
mitochondrial oxidative stress. Rotenone is a naturally 
occurring isoflavone that behaves as an inhibitor of 
complex I, which strongly induces mitochondrial 
oxidative stress [9]. Rotenone is also an environmental 
pollutant, as it is frequently used as a broad-spectrum 
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ment, mitochondrial complexes I and III are the major 
sites of electron leakage, resulting in increased 
superoxide production [11]. 
 
We treated MCF7 cells with increasing concentrations 
of Rotenone. Interestingly, low-dose Rotenone (1 or 2.5 
nM) was indeed sufficient to stimulate mammosphere 
formation, by ~1.6 to 1.8-fold (Figure 6). However, 
higher doses of Rotenone (10-100 nM) inhibited 
mammosphere formation, as expected, due to 













































To further validate that the effects of low-dose Rotenone 
were due to oxidative stress, we also used a mitochon-
drial-specific anti-oxidant, namely Mito-tempo. More 
specifically, Mito-tempo functions as a ROS scavenger, 
by targeting superoxide anions generated in mitochondria 
[12].  Figure 7 highlights that treatment with Mito-tempo 
(100 μM) was indeed sufficient to inhibit the stimulatory 
effects of Rotenone (1 nM) on MCF7 mammosphere 
formation. Virtually identical effects were also observed 
with Doxycycline (50 μM), which functions as a known 













































Figure  7.  Rotenone‐enhanced  mammosphere  formation  is  ablated  by  treatment  with  Doxycycline  or  Mito‐
tempo.  (A) MCF7 cells were pre‐treated  for 48 hours with Rotenone  (from 1 to 4 nM) as a monolayer. Then the cells were
harvested  by  trypsinization  and  re‐plated  under  low‐attachment  conditions  for  the  mammosphere  assay.  Note  that  pre‐
treatment of MCF7 monolayers with  rotenone at either 1 or 2 nM stimulated mammosphere  formation.  (B) As  in panel  (A),
except the MCF7 monolayers were pre‐treated for 48 hours with Rotenone (1 nM). Then, the cells were re‐plated under low‐
attachment conditions. Note that further treatment with i) an inhibitor of mitochondrial biogenesis (Doxycycline; 50 μM) or ii) a
mitochondrial‐based antioxidant (Mito‐tempo; 100 μM), is sufficient to block Rotenone‐enhanced mammosphere formation.  
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Clinical relevance of c-Myc mitochondrial targets in 
human breast cancers 
 
To determine the potential clinical relevance of our 
findings, we next assessed whether the c-Myc 
mitochondrial targets that we identified in MCF7 cells 
were also transcriptionally up-regulated in human breast 
cancer cells in vivo. 
 
For this purpose, we employed a published clinical data 
set of N=28 breast cancer patients in which their tumor 












































tion, to physically separate epithelial cancer cells from 
their adjacent tumor stroma.  Table 2 presents a 
summary of these findings.  
 
Overall, nearly 80% of the c-Myc mitochondrial 
targets that we identified in MCF7 cells in vitro were 
also transcriptionally elevated in human breast cancer 
cells in vivo (20 out of 26, ~77%). This observation 
provides a strong indication that the mitochondrial 
Myc-targets that we identified here are of high trans-















































Symbol  Gene Probe    HR (Hazard Ratio)  P-value (Log Rank Test) 
 
HSPD1  200807_s_at    3.46    1.3e-05 
HSPD1   200806_s_at    2.34    0.0049 
TIMM44 203093_s_at    2.51    0.0042 
COX5B  213735_s_at    2.51    0.0012 
COX5B  202343_x_at    2.30    0.0032 
COX5B  211025_x_at    2.13    0.0077 
IDH3A   202069_s_at    2.46    0.0026 
IDH3A   202070_s_at    2.25    0.0089 
TRAP1  221235_s_at    1.77    0.048 
 
Figure  8.  Flow‐diagram  illustrating  our  overall  approach  to  Myc‐driven  biomarker  discovery.  In  this  analysis,  we
focused specifically on ER(+) patients,  luminal A sub‐type,  that were  lymph‐node positive  (LN(+)) at diagnosis, who were  treated
with tamoxifen and followed over a period of nearly 200 months (>15 years). In this context, we evaluated the prognostic value of
Myc‐related mitochondrial markers for predicting tumor recurrence (RFS) or distant metastasis (DMFS), in this patient population. 
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Prognostic value of c-Myc-induced mitochondrial 
targets in human breast cancer patients: 
Implications for treatment failure and distant 
metastasis 
 
Next, we assessed the prognostic significance of the c-
Myc-induced mitochondrial targets that we identified by 
proteomics analysis. A work-flow diagram briefly 
illustrating our overall informatics-based approach to 
oncogene-driven breast cancer biomarker discovery is 
shown in Figure 8.  
 
More specifically, we used publically available 
transcriptional profiling data from the tumors of breast 









































not receive any chemotherapy.  For this purpose, we 
selected high-risk patients that were lymph-node 
positive at diagnosis, and we focused on the luminal A 
subtype, which represents the most common form of 
ER(+) breast cancers (N=152 patients). Using this 
systematic approach, we identified 5 gene transcripts 
and 9 gene probes that showed high prognostic value 
(Table 3).  
 
In order to increase the prognostic power of these 
individual mitochondrial biomarkers, we next selected 
the most promising ones and used them to create a new 
c-Myc-based Mito-Signature that contains 3 genes 
(Summarized in Tables 4 & 5). This Mito-Signature 










































Symbol Gene Probe HR (Hazard Ratio) P-value (Log Rank Test) 
    
HSPD1 200807_s_at 3.46 1.3e-05 
COX5B  213735_s_at 2.51 0.0012 
TIMM44 203093_s_at 2.51 0.0042 




recurrence  and distant metastasis  in  ER(+)/LN(+)/luminal A  patients  treated with  tamoxifen  therapy,  indicative  of
treatment failure and tamoxifen‐resistance. RFS, recurrence‐free survival; DMFS, distant metastasis‐free survival.  
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(HSPD1), with ii) an OXPHOS subunit  (COX5B; from 
Complex IV) and iii) a marker of mitochondrial 
biogenesis (TIMM44; Translocase Of Inner 
Mitochondrial Membrane 44).  
 
Briefly, Figure 9 (left panel) shows the results of this K-
M analysis for relapse-free survival (RFS) for the Myc-
based Mito-Signature (HR=4.69; p=2.4e-08). Similar 
results were also obtained for distant metastasis-free 
survival (DMFS) (HR=4.94; p=2.8e-07) (Figure 9, right 
panel). Therefore, this Myc-based Mito-Signature was 
very effective at predicting tamoxifen-resistance and 
treatment failure for endocrine therapy.  
 










































Myc-based Mito-Signature in even larger and more 
varied patient populations, where the therapy was not 
restricted to tamoxifen. Importantly, Figure 10 
illustrates that the Myc Mito-Signature was also 
effective in both ER(+) (N=3,082; HR=1.81; p<1e-16) 
and ER(-)/basal (N=618; HR=1.53; p=0.00091) breast 
cancer populations, as well as in all breast cancer 
subtypes combined (N=3,951; HR=1.71; p<1e-16; See 
Supplementary Figure S1). 
 
As such, this Myc-based mitochondrial gene signature 
may represent an important new prognostic tool for 
predicting patient outcomes, in a wide variety of 
different breast cancer patient populations, as well as in 









































Symbol  Gene Probe    HR (Hazard Ratio)  P-value (Log Rank Test) 
 
HSPD1  200807_s_at    3.50    9.7e-05 
COX5B  213735_s_at    3.20    0.00075 
TIMM44 203093_s_at    3.06    0.0024 




breast  cancer  patients.    Note  that  this  short  3‐gene  signature  (HSPD1/COX5B/TIMM44)  also  effectively  predicts  tumor
recurrence in larger populations of both ER(+) [N=3,082] and ER(‐) [N=618] breast cancer patients. RFS, recurrence‐free survival. 
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DISCUSSION 
 
MYC/RAS co-operativity: focus on stemness and 
cellular metabolism 
 
To mechanistically determine exactly how MYC/RAS 
co-operativity contributes to stemness in breast cancer 
cells, we used MCF7 cells as a model system. Briefly, 
we generated a panel of MCF7 cell lines transduced 
with c-Myc or H-Ras (G12V), either individually or in 
combination. In this context, the mammosphere assay 
(3D spheroid formation) was used as a standard 
measure of CSC activity. c-Myc increased both 
mitochondrial respiration and mammosphere formation, 
without changing glycolytic flux. Surprisingly, H-Ras 
(G12V) alone did not affect glycolysis or either 
mammosphere formation. Interestingly, H-Ras (G12V) 
stimulated both glycolysis and mammosphere 
formation, but only when combined with c-Myc.  
 
These findings provide novel insight into how 
MYC/RAS co-operativity synergistically drives changes 
in stemness and cellular metabolism. Since it is well-
established that c-Myc exerts some of its effects by 
increasing mitochondrial biogenesis, we also 
determined the activity of another stimulus that drives 
mitochondrial biogenesis, namely oxidative stress.  
 
A phenotypic approach to cancer therapy: targeting 
mitochondrial biogenesis 
 
To chemically induce mitochondrial oxidative stress, 
we used a well-known mitochondrial poison (Rotenone) 
to inhibit the function of mitochondrial complex I. 
Rotenone treatment yielded bi-phasic effects; low-dose 
Rotenone (1-2.5 nM) increased mammosphere 
formation, while higher doses (10-100 nM) were 
inhibitory. Next, we experimentally confirmed the 
hypothesis that mitochondrial biogenesis was absolutely 
necessary to stimulate CSC propagation, by employing 
Doxycycline, a safe FDA-approved inhibitor of mito-
chondrial protein translation [13]. 
 
Doxycycline treatment was sufficient to block the 
positive effects of H-Ras (G12V), c-Myc, and Rotenone 
on CSC propagation (Figure 11).  As such, our results 
with Doxycycline treatment provide an impetus for the 
creation of novel therapies to target mitochondrial 
protein translation in CSCs.  
 
Our results also directly support the idea of a “mutation-
independent” approach to cancer therapy. Importantly, 
most effective cancer therapies used today target 
“cancer cell behaviors”, such as increased cell 
proliferation, rather than particular genetic mutations. 
Thus, we propose that a cell-based “phenotypic 
approach” towards generating new cancer therapies 































Interestingly, previous studies conducted by Porporato 
et al., 2014, have reported that the pre-treatment of 
B16F10 melanoma cells with low-dose Rotenone (in the 
10-100 nM range) for only 6 hours resulted in dramatic 
increases in cell migration, invasion and lung metastasis 
[14]. Importantly, this pro-metastatic effect of short 
exposure to low-dose Rotenone could be prevented or 
reversed by employing Mito-tempo, a mitochondrial-
specific anti-oxidant targeting superoxide anions [15]. 
 
These results are consistent with our current findings, 
although these authors did not mechanistically 
determine the effects of Rotenone on CSC propagation. 
Also, these authors did not examine the effects of 
Doxycycline on the pro-metastatic activity conferred by 
Rotenone pre-treatment. However, taken together, these 
data suggest that Doxycycline treatment may be very 
useful for preventing the development of metastatic 
disease.  
 
In direct support of this assertion, earlier studies have 
shown that Doxycycline treatment can effectively 
prevent bone metastasis in a preclinical animal model, 
using MDA-MB-231 human breast cancer cells [16]. 
Figure 11. MYC‐RAS co‐operativity “fuels” stemness  in 
cancer  cells:  Mutation‐independent  cancer  therapy,
with  Doxycycline.  Here,  we  show  that  either  a  i)  genetic 
stimulus [oncogene activation (c‐Myc or H‐Ras (G12V)] or an ii) 
environmental  stimulus  [mitochondrial  oxidative  stress
(chemically induced by Rotenone)] are both sufficient to drive 
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Therefore, further experimentation and clinical trials 
may be warranted, to explore the role of Doxycycline in 
the prevention and treatment of metastatic disease.  
 
Biomarker discovery & companion diagnostics:  a 
“Proteomics-to-Genomics (PTG)” approach for in 
silico validation 
 
Here, we used unbiased proteomics analysis of MCF7 
cells stably transduced with c-Myc to identify new 
mitochondrial targets in human breast cancer cells. 
Using this approach, we identified 26 mitochondrial 
proteins that were specifically up-regulated in MCF7-c-
Myc cells, relative to MCF7 control cells transduced 
with the vector alone.   
 
To validate the translational and clinical relevance of 
our findings, we next intersected this proteomics data 
set, with independent transcriptional profiling data 
obtained via the laser capture of human breast cancer 
cells, from excised tumor tissue. Interestingly, our 
results indicated that 20 out of 26 proteins that were up-


































tionally up-regulated in human breast cancer cells, 
relative to adjacent tumor stromal cells.  
 
To provide in silico validation of the prognostic value 
of these Myc-based targets, we also intersected our 
proteomic data with transcriptional profiling data 
obtained from tumor samples, linked to clinical 
outcome (Figures 12 and 13). This “Proteomics-to-
Genomics (PTG)” approach allowed us to determine the 
prognostic value of these 26 mitochondrial proteins, 
either individually and/or in various combinations. 
Using this systematic approach, we identified 5 gene 
transcripts and 9 gene probes that showed high 
prognostic value. The prognostic value of these bio-
markers was also enhanced significantly, by using more 
than one mitochondrial marker in combination, by 
forming a short signature.  
 
Remarkably, this Myc-based Mito-Signature was very 
effective at predicting tamoxifen-resistance and 
treatment failure for endocrine therapy in ER(+) breast 
cancer patients. Importantly, this Myc-based Mito-


































This simplified strategy can be potentially applied  to any cancer  type. The  first step  involves  the generation of a
novel  cellular model, which  is  interrogated by proteomics analysis. Then,  these  results are used  to establish  the
prognostic  value  of  these  candidate  biomarkers,  by  searching  pre‐existing  human  transcriptional  profiling  data,
linked  to  clinical outcome  (in  silico  validation).  The prognostic  value of  these biomarkers  can  also be  enhanced
significantly,  by  using  more  than  one  marker  in  combination,  forming  a  short  signature.  This  “Proteomics‐to‐
Genomics (PTG)” approach then efficiently yields new targets and biomarkers, linked to parameters associated with
clinical outcome (tumor recurrence, distant metastasis, overall survival, or response to therapy).  
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ER(+) (N=3,082) and ER(-) (N=618) breast cancer 
patients. As a result, this Myc-based mitochondrial gene 
signature may represent an important new companion 
diagnostic for predicting patient outcomes and the 
response to anti-mitochondrial therapy, in a wide 



















































Advantages to using the “Proteomics-to-Genomics 
(PTG)” strategy 
 
The “central dogma of molecular biology” teaches us 
that i) genes are encoded within genomic DNA, ii) that 





















































directly  used  to  interrogate  existing  genomics  data  (transcriptional  profiling)  from  clinical  samples,
which are  linked  to  follow‐up data. This approach directly allows  for  the  in  silico  validation of  i)  the
prognostic  value  (of  a  given  candidate  biomarker)  and  ii)  helps  to  generate  new  targets  for  drug
discovery, by directly demonstrating their clinical relevance.  
Figure  14.  mRNA levels  do  not  correlate  with  protein
levels,  creating  a  bottle‐neck  for  protein  biomarker
discovery.  (A)  Concordance  between  mRNA  and  protein  is
actually  quite  variable  and  completely  unpredictable,  ranging
anywhere between 0 and 100%. This discordance between mRNA
and protein expression  levels ultimately makes  it very difficult or
nearly  impossible,  to  use  transcriptional  profiling  data  for  the
development  of  new  protein  biomarkers  as  companion
diagnostics.    (B)  Our  new  “Proteomics‐to‐Genomics  (PTG)”




tight  correlations,  nearing  100%.  It  essentially  allows  one  to
“work‐backwards”,  providing  a much  needed  systematic  “short‐
cut” to protein biomarker discovery.  
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RNA-polymerase, iii) which is then later translated into 
protein by ribosomes (Figure 14). Thus, one would 
initially assume or predict that mRNA levels would 
directly correlate with protein levels. However, if you 
experimentally construct a plot of the levels of an 
mRNA species encoding a given gene product, versus 
its actual protein levels, the correlation coefficient (R) is 
normally less than 0.50 or 50% [17-21].  As such, the 
concordance between mRNA and protein is actually 
quite variable and completely unpredictable, ranging 
anywhere between 0 and 100% [17-21]. This 
discordance between mRNA and protein expression 
levels ultimately makes it very difficult or nearly 
impossible, to use transcriptional profiling data for the 
development of new protein biomarkers as companion 
diagnostics.   
 
Our new “Proteomics-to-Genomics (PTG)” strategy 
provides a simple straightforward solution to this 
practical problem. By starting out with proteomics data 
first and then integrating it with existing transcriptional 
profiling data, this allows one to quickly identify and 
select a sub-set of genes, with tight correlations, nearing 
100%.   
 
With this approach, one already knows a priori that the 
protein product is over-expressed, even before 
correlating it with transcriptional profiling data. It 
essentially allows one to “work-backwards”, providing 
a much needed systematic “short-cut” to protein 
biomarker discovery. This could help remove the bottle-
neck on the route to successful companion diagnostics.  
 
Implications for understanding oncogenic stress and 
senescence 
 
Oncogene expression in normal cells results in 
excessive cellular stress, usually leading to ROS over-
production, driving either i) cell death via apoptosis, ii) 
cell-cycle arrest via senescence or iii) the activation of 
autophagic/mitophagic survival programs [22-24]. One 
important mechanism by which CSCs escape from 
oncogenic stress is through cell immortalization, via the 
over-expression or activation of telomerase activity 
(e.g., hTERT) [22-24]. This may ultimately explain why 
stem cells are the ultimate target of oncogenes, as non-
stem cells cannot survive oncogenic stress, because they 
lack sufficient telomerase activity. Oncogenes simply 
kill most non-stem cells, leaving behind only surviving 
stem-like cells, which are the only cell type that is 
resistant to, or effectively tolerates,  oncogenic stress.  
 
Recently, we showed that CSCs with high telomerase 
activity also show high mitochondrial mass. Interest-
ingly, the survival effects conferred by hTERT-
expression in CSCs could be overcome, simply by 
treatment with an inhibitor of mitochondrial biogenesis, 
namely Doxycycline [25]. Similar results were obtained 
with Palbociclib, a CDK4/6 inhibitor [25]. Therefore, 
the survival effects conferred by telomerase in CSCs 
can be mechanistically reversed by chemically inducing 
cell-cycle arrest (Palboiclib) or mitochondrial dys-
function (Doxycycline).  
 
In summary, inhibition of either “cellular proliferation” 
or “mitochondrial proliferation” is sufficient to block 
CSC propagation. These observations provide further 
experimental support for a mutation-independent 
approach to cancer therapy, by phenotypically targeting 
CSCs. 
 




MCF7 cells were purchased from the ATCC (American 
Type Culture Collection). Gibco-brand cell culture 
media (DMEM) was purchased from Life Technologies.  
 
Lentiviral gene transduction 
 
Lentiviral plasmids, packaging cells and reagents were 
purchased from Genecopoeia, Inc. Forty-eight hours 
after seeding, 293Ta packaging cells were transfected 
with lentiviral vectors encoding c-Myc, H-Ras (G12V) 
or the empty vector (EX-NEG-Lv105-PURO), using 
Lenti-PacTM HIV Expression Packaging Kit, according 
to the manufacturer's instructions. Two days post-
transfection, lentivirus-containing culture medium was 
passed through a 0.45 μm filter and added to the target 
cells (MCF-7 cells) in the presence of 5 μg/ml 
Polybrene. Infected cells were selected with a con-
centration of 1.5 μg/ml of puromycin. After puromycin-
resistant cells were growing continuously, a population 
of MYC transfected cells or control cells were further 
infected with medium of 293Ta cells transfected with an 
H-Ras (G12V) lentiviral vector or empty vector (EX-
NEG-Lv151-NEO) (virus produced, as same above). 
Double-transfected c-Myc/H-Ras (G12V) MCF7 cells 
were then selected with Geneticin (G418). These MCF7 
cell lines were originally generated at the University of 
Manchester.  
 
Mammosphere formation assay 
 
A single cell suspension of MCF7 cells was prepared 
using enzymatic (1x Trypsin-EDTA, Sigma Aldrich) 
and manual disaggregation with a 25 gauge needle. 
Cells were then plated at a density of 500 cells/cm2 in 
mammosphere medium (DMEM-F12/ B27 / 20-ng/ml 
EGF/PenStrep) in non-adherent conditions, in culture 
dishes coated with (2-hydroxyethylmethacrylate) (poly-
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HEMA, Sigma). Cells were grown for 5 days and 
maintained in a humidified incubator at 37°C at an 
atmospheric pressure in 5% (v/v) carbon dioxide/air. 
After 5 days in culture, spheres >50 μm were counted 
using an eye-piece graticule, and the percentage of cells 
plated which formed spheres was calculated and is 
referred to as percent mammosphere formation, nor-
malized to vehicle-alone treated controls. Mammo-
sphere assays were performed in triplicate and repeated 
three times independently. 
 
Seahorse XFe96 metabolic flux analysis 
 
Extracellular acidification rates (ECAR) and real-time 
oxygen consumption rates (OCR) for MCF7 cells were 
determined using the Seahorse Extracellular Flux 
(XF96) analyzer (Seahorse Bioscience, MA, USA). 
MCF7 cells were maintained in DMEM supplemented 
with 10% FBS (fetal bovine serum), 2 mM GlutaMAX, 
and 1% Pen- Strep. 8,000 cells per well were seeded 
into XF96-well cell culture plates, and incubated 
overnight at 37°C in a 5% CO2 humidified atmosphere. 
Next day, cells were washed in pre-warmed XF assay 
media (for OCR measurement, XF assay media was 
supplemented with 10mM glucose, 1mM Pyruvate and 
adjusted at pH 7.4). Cells were then maintained in 175 
μL/well of XF assay media at 37°C, in a non-CO2 
incubator for 1h. During incubation, 25 μL of of 80mM 
glucose, 9μM oligomycin, 1M 2-deoxyglucose (for 
ECAR measurement) and 25 μL of 10μM oligomycin, 
9μM FCCP, 10μM rotenone, 10μM antimycin A (for 
OCR measurement) in XF assay media was loaded into 
the injection ports of the XFe-96 sensor cartridge. 
During the experiment, the instrument injected these 
inhibitors into the wells at a given time point, while 
ECAR/OCR was measured continuously. ECAR and 
OCR measurements were normalized by protein content 
(Sulphorhodamine B assay). Data sets were analyzed by 
XFe-96 software, using one-way ANOVA and 
Student’s t-test calculations. All experiments were 
performed in triplicate. 
 
Global semi-quantitative proteomics analysis 
 
Cell lysates were prepared for trypsin digestion by 
sequential reduction of disulphide bonds with TCEP 
and alkylation with MMTS. Then, the peptides were 
extracted and prepared for LC-MS/MS. All LC-MS/MS 
analyses were performed on an LTQ Orbitrap XL mass 
spectrometer (Thermo Scientific, San Jose, CA) coupled 
to an Ultimate 3000 RSLCnano system (Thermo 
Scientific, formerly Dionex), The Netherlands). 
Xcalibur raw data files acquired on the LTQ-Orbitrap 
XL were directly imported into Progenesis LCMS 
software (Waters Corp., Milford, MA, formerly 
Nonlinear dynamics, Newcastle upon Tyne, UK) for 
peak detection and alignment. Data were analyzed using 
the Mascot search engine. Five technical replicates were 
analyzed for each MCF7 sample (c-Myc transduced vs. 




To firmly establish the clinical relevance of our results 
from the proteomics analysis of MCF7 cells harboring 
c-Myc, we re-analyzed the transcriptional profiles of 
epithelial breast cancer cells and adjacent tumor stromal 
cells that were physically separated by laser-capture 
microdissection (from N=28 human breast cancer 
patients) [26]. 
 
Kaplan-Meier (K-M) analyses 
 
To perform K-M analysis nuclear mitochondrial gene 
transcripts, we used an open-access online survival 
analysis tool to interrogate publically available 
microarray data from up to 3,951 breast cancer patients 
[27]. This allowed us to determine their prognostic 
value. For this purpose, we primarily analyzed data 
from ER(+) patients that were LN(+) at diagnosis and 
were of the luminal A sub-type, that were primarily 
treated with tamoxifen and not other chemotherapy 
(N=152 patients). In this group, 100% the patients 
received some form of hormonal therapy and >90% of 
them received tamoxifen. Biased and outlier array data 
were excluded from the analysis. Hazard-ratios were 
calculated, at the best auto-selected cut-off, and p-
values were calculated using the logrank test and plotted 
in R.  K-M curves were also generated online using the 





This allowed us to directly perform in silico validation 
of these mitochondrial biomarker candidates.  The 
multi-gene classifier function of the program was used 
to test the prognostic value of short mitochondrial gene 
signatures, using the mean expression of the selected 
probes. The most updated version of the database was 
utilized for these analyses; however, these studies were 
originally performed in 2014 and virtually identical 
results were obtained with the 2012 and 2014 versions 




Statistical significance was determined using the 
Student’s t-test, values of less than 0.05 were 
considered significant. Data are shown as the mean ± 
SEM, unless stated otherwise.  
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SUPPLEMENTARY MATERIAL 
 
 
 
Supplementary Figure S1. A short c‐Myc‐related mitochondrial signature predicts
poor clinical outcome, in all breast cancer sub‐types, when combined.  Note that this
short 3‐gene signature (HSPD1/COX5B/TIMM44) also effectively predicts tumor recurrence in
a larger population of breast cancer patients (N=3,951). RFS, recurrence‐free survival. 
